Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Ana B Oton

TitleAffiliate
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-MED
    Other Positions
    TitleAffiliate - DHHA
    InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
    DepartmentSOM-MED
    DivisionOncology


    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Hess LM, Kern DM, Carter GC, Winfree K, Wang L, Sontag A, Oton AB. Real-World Treatment Sequences and Outcomes Among Patients With Non-Small Cell Lung Cancer (RESOUNDS) in the United States: Study Protocol. JMIR Res Protoc. 2017 Oct 11; 6(10):e195. PMID: 29021129.
      View in: PubMed
    2. Hess LM, Cui ZL, Wu Y, Fang Y, Gaynor PJ, Oton AB. Current and projected patient and insurer costs for the care of patients with non-small cell lung cancer in the United States through 2040. J Med Econ. 2017 Aug; 20(8):850-862. PMID: 28532187.
      View in: PubMed
    3. Langer CJ, Paz-Ares LG, Wozniak AJ, Gridelli C, de Marinis F, Pujol JL, San Antonio B, Chen J, Liu J, Oton AB, Visseren-Grul C, Scagliotti GV. Safety Analyses of Pemetrexed-cisplatin and Pemetrexed Maintenance Therapies in Patients With Advanced Non-squamous NSCLC: Retrospective Analyses From 2 Phase III Studies. Clin Lung Cancer. 2017 Sep; 18(5):489-496. PMID: 28479368.
      View in: PubMed
    4. Hess LM, Louder A, Winfree K, Zhu YE, Oton AB, Nair R. Factors Associated with Adherence to and Treatment Duration of Erlotinib Among Patients with Non-Small Cell Lung Cancer. J Manag Care Spec Pharm. 2017 Jun; 23(6):643-652. PMID: 28530522.
      View in: PubMed
    5. Hess LM, Cui Z, Wu Y, Fang Y, Gaynor P, Oton AB. PS01.72: Payer and Patient Out-of-Pocket Costs: A Projection of the Financial Burden of Non-Small Cell Lung Cancer Care in the United States Through 2040: Topic: Medical Oncology. J Thorac Oncol. 2016 Nov; 11(11S):S315-S316. PMID: 27969539.
      View in: PubMed
    6. Rolfo C, Caglevic C, Bretel D, Hong D, Raez LE, Cardona AF, Oton AB, Gomez H, Dafni U, Vallejos C, Zielinski C. Cancer clinical research in Latin America: current situation and opportunities. Expert opinion from the first ESMO workshop on clinical trials, Lima, 2015. ESMO Open. 2016; 1(4):e000055. PMID: 27843620.
      View in: PubMed
    7. Lopez-Chavez A, Thomas A, Evbuomwan MO, Xi L, Chun G, Vidaurre T, Arrieta O, Oblitas G, Oton AB, Calvo AR, Rajan A, Raffeld M, Steinberg SM, Arze-Aimaretti L, Giaccone G. EGFR Mutations in Latinos From the United States and Latin America. J Glob Oncol. 2016 Oct; 2(5):259-267. PMID: 28717712.
      View in: PubMed
    8. Weickhardt AJ, Doebele RC, Purcell WT, Bunn PA, Oton AB, Rothman MS, Wierman ME, Mok T, Popat S, Bauman J, Nieva J, Novello S, Ou SH, Camidge DR. Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients. Cancer. 2013 Jul 01; 119(13):2383-90. PMID: 23585220; PMCID: PMC3686910.
    9. Weickhardt AJ, Rothman MS, Salian-Mehta S, Kiseljak-Vassiliades K, Oton AB, Doebele RC, Wierman ME, Camidge DR. Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer. 2012 Nov 01; 118(21):5302-9. PMID: 22488744.
      View in: PubMed
    10. Weickhardt A, Doebele R, Oton A, Lettieri J, Maxson D, Reynolds M, Brown A, Jackson MK, Dy G, Adjei A, Fetterly G, Lu X, Franklin W, Varella-Garcia M, Hirsch FR, Wynes MW, Youssoufian H, Adjei A, Camidge DR. A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2012 Feb; 7(2):419-26. PMID: 22237261; PMCID: PMC3358820.
    11. Doebele RC, Lu X, Sumey C, Maxson DA, Weickhardt AJ, Oton AB, Bunn PA, Barón AE, Franklin WA, Aisner DL, Varella-Garcia M, Camidge DR. Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer. 2012 Sep 15; 118(18):4502-11. PMID: 22282022; PMCID: PMC3370097.
    12. Camidge DR, Kono SA, Lu X, Okuyama S, Barón AE, Oton AB, Davies AM, Varella-Garcia M, Franklin W, Doebele RC. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol. 2011 Apr; 6(4):774-80. PMID: 21336183; PMCID: PMC3626562.
    13. Calverley DC, Phang TL, Choudhury QG, Gao B, Oton AB, Weyant MJ, Geraci MW. Significant downregulation of platelet gene expression in metastatic lung cancer. Clin Transl Sci. 2010 Oct; 3(5):227-32. PMID: 21500395; PMCID: PMC3427741.
    14. Doebele RC, Oton AB, Peled N, Camidge DR, Bunn PA. New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer. Lung Cancer. 2010 Jul; 69(1):1-12. PMID: 20092908.
      View in: PubMed
    15. Peled N, Oton AB, Hirsch FR, Bunn P. MAGE A3 antigen-specific cancer immunotherapeutic. Immunotherapy. 2009 Jan; 1(1):19-25. PMID: 20635969.
      View in: PubMed
    16. Oton AB, Wang H, Leleu X, Melhem MF, George D, Lacasce A, Foon K, Ghobrial IM. Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders in solid transplant. Leuk Lymphoma. 2008 Sep; 49(9):1738-44. PMID: 18798108.
      View in: PubMed
    17. Alsayed Y, Leleu X, Leontovich A, Oton AB, Melhem M, George D, Ghobrial IM. Proteomics analysis in post-transplant lymphoproliferative disorders. Eur J Haematol. 2008 Oct; 81(4):298-303. PMID: 18573174.
      View in: PubMed
    18. Owonikoko TK, Ragin CC, Belani CP, Oton AB, Gooding WE, Taioli E, Ramalingam SS. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol. 2007 Dec 10; 25(35):5570-7. PMID: 18065729.
      View in: PubMed
    19. Feng R, Oton A, Mapara MY, Anderson G, Belani C, Lentzsch S. The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage. Br J Haematol. 2007 Nov; 139(3):385-97. PMID: 17910628.
      View in: PubMed
    Oton's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _

    Copyright © 2017 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.10.0)